Fourth Monitoring Agency Report confirms ongoing utilisation of Rs 117.01 crore raised via preferential issue and CCDs as of Q4 FY2026, with regulatory oversight and standard disclosures continuing to external stakeholders.
AI Assistant
Beta Drugs Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.